Solvent Effect on Selectivity of Grignard Reaction for Pharmaceutical Intermediate Synthesis in Batch Reactor

Abstract

The Grignard reaction is a widely employed synthetic route in pharmaceutical manufacturing for the preparation of complex organic intermediates with high functional specificity. This study investigates the influence of solvent selection on the selectivity and performance of Grignard reactions during pharmaceutical intermediate synthesis in a batch reactor system. The research focuses on understanding how solvent polarity, dielectric properties, coordination ability, and reaction environment affect reaction kinetics, product distribution, and by-product formation. Experimental studies were conducted using different ether-based and aprotic solvents under controlled temperature, agitation, and reactant concentration conditions to evaluate their impact on reaction efficiency and selectivity. The results demonstrated that solvent characteristics significantly influence the stability of organomagnesium intermediates and the overall progression of the Grignard reaction. Certain solvents enhanced product selectivity by improving reagent solubility and reducing undesirable side reactions, while others promoted competing pathways that decreased yield and purity. Kinetic analysis and mechanistic evaluation revealed that solvent–solute interactions play a critical role in controlling reaction rates, heat transfer behavior, and intermediate complex formation within the batch reactor. The optimized solvent system achieved improved conversion efficiency, higher selectivity toward the desired pharmaceutical intermediate, and reduced impurity generation. Furthermore, the study emphasizes the importance of solvent engineering in enhancing process safety, scalability, and economic feasibility in pharmaceutical synthesis operations. The findings provide valuable insights for the development of efficient batch reactor processes and support the optimization of Grignard-based manufacturing strategies in fine chemical and pharmaceutical industries.